Axim Biotechnologies, Inc. · OTC:AXIM
Axim Biotechnologies — Investor Presentation (January 2019)
13 slides from Axim Biotechnologies's investor presentation, January 2019
Slide 1: Management Presentation
Better Delivery, Safer Treatments, Healthier Lives Management Presentation January 2019
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of AXIM’s management and are subject to si
Slide 3: About AXIM Biotech
ABOUT AXIM BIOTECH AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid- based pharmaceutical products. Along with building a robust intellectual property portfolio, AXIM is focused on clinical development programs that bring more efficacy and/or lower
Slide 4: Our Flagship Products
OUR FLAGSHIP PRODUCTS Focused clinical development program with 3 flagship products formulated and ready for further research MedChew® with Dronabinol Dronabinol-based gum that utilizes AXIM’s proprietary chewing 1 gum delivery system aiming to be bioequivalent to an FDA- approved medication treatin
Slide 5: Strategic Advantages
STRATEGIC ADVANTAGES Intellectual Property Proven Delivery System Technology Regulatory Approvals & • Worldwide patent on cannabinoid-based Certifications • AXIM developed a transmucosal, controlled • Meets compliance and quality standards chewing gum delivery system release delivery system for cann
Slide 6: Short and Mid-Term Strategic Positioning
SHORT AND MID-TERM STRATEGIC POSITIONING Focused business plan, to be Maximize the use of patented Strategic project selection, that Utilize existing and additional Monetize all existing implemented by incoming transmucosal, controlled- has a +60% chance of being partnerships for further nutraceutic
Slide 7: Short & Mid-Term Product Pipeline
SHORT & MID-TERM PRODUCT PIPELINE Drug Application Indication Pre-clinical Formulation Bioequivalence Market MedChew w/Dronabinol Chewing Gum Nausea/Vomiting/Loss of Appetite Drug Application Indication Pre-clinical Phase 1 Phase 2 Phase 3 MedChew RL Chewing Gum Restless Leg Syndrome MedChew Rx Chew
Slide 8: Market Analysis
MARKET ANALYSIS Pharmaceutical Pipeline $1.7 Bn $700 Mn $27.38 Bn $6.8 Bn Multiple Sclerosis market by Global Drug-Related Nausea/Vomiting/Loss of Restless Leg Syndrome Psychosis market in 2016 Appetite (Source) Global Market Size (Source) 2025 from $16.3 Billion in 2017 with CAGR of 6.3% (Source) w
Slide 9: Competitive Analysis
COMPETITIVE ANALYSIS The average market cap of the 3 leading medical CBN public companies (GWPH, INSY, ZYNE) is $1.42 billion Pharmaceutical The average market cap of the 3 leading consumer CBN public companies (CVSI, ELLXF, USNA) is $1.14 billion Nutraceutical
Slide 10: Prioritizing in Focus Areas, Reducing Operating Expenses
PRIORITIZING IN FOCUS AREAS, REDUCING OPERATING EXPENSES In the short term, AXIM has identified the projects that have the best chance to make it to market within 24-48 months, with remaining initiatives moved to future development phases. For current or upcoming Phase I trials, AXIM has selected: 1
Slide 11: Proven Management Team
PROVENMANAGEMENT TEAM c George Anastassov, MD, DDS, MBA John W. Huemoeller II Lekhram Changoer, MSC, BSC Philip Van Damme, DMD, MD, PhD Founder | Chairman of the Board Chief Executive Officer Director, Chief Technology Officer Director, Chief Medical Officer Co-founder, CEO of CanChew Over 35 years
Slide 12: World Renowned Advisory Board
WORLD RENOWNED ADVISORY BOARD Renger Witkamp, Professor Chair in Nutrition and Pharmacology at Wageningen University, the best university in the Netherlands and No. 1 worldwide in agriculture and forestry John Zajicek, Professor Vice Dean Research and Chair of Clinical Neuroscience with the Plymouth
Slide 13: For further information, please contact
For further information, please contact: Tel. +1 844 294 6246 [email protected] www.aximbiotech.com North American Address: 45 Rockefeller Plaza, 20th Floor, New York, NY 10111, USA +1 844 294 6246 European Address: Boelewerf 32, Unit 3, 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
AXIM Biotechnologies — Investor Presentation (January 2019) on 6ix